Your browser doesn't support javascript.
loading
Perspectives on shorter durations of anti-HER2 therapy in early-stage HER2-positive breast cancer: a patient survey.
Bradbury, M; Savard, M F; Stober, C; Clemons, L; Clemons, M; Hilton, J; Pond, G; Vandermeer, L; McGee, S F.
Afiliação
  • Bradbury M; Department of Medicine, Division of Internal Medicine, The Ottawa Hospital, University of Ottawa, Ottawa, Canada.
  • Savard MF; Department of Medicine, Division of Medical Oncology, The Ottawa Hospital, University of Ottawa, Ottawa, Canada.
  • Stober C; Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, Canada.
  • Clemons L; Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, Canada.
  • Clemons M; Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, Canada.
  • Hilton J; Department of Medicine, Division of Medical Oncology, The Ottawa Hospital, University of Ottawa, Ottawa, Canada.
  • Pond G; Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, Canada.
  • Vandermeer L; Department of Medicine, Division of Medical Oncology, The Ottawa Hospital, University of Ottawa, Ottawa, Canada.
  • McGee SF; Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, Canada.
Breast Cancer Res Treat ; 206(3): 473-481, 2024 Aug.
Article em En | MEDLINE | ID: mdl-38664288
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Receptor ErbB-2 Limite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Receptor ErbB-2 Limite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Ano de publicação: 2024 Tipo de documento: Article